Product Name
|
CAS Number
|
Exterior
|
Product Purity
|
Efficacy/Use
|
---|---|---|---|---|
Semaglutide
new
|
910463-68-2
|
White Powder
|
API QC
|
GLP-1, GIP, GCG single target, dual target, three target receptor agonists, weight loss
|
Terzapitide
new
|
2023788-19-2
|
White Powder
|
API QC
|
GLP-1, GIP, GCG single target, dual target, three target receptor agonists, weight loss
|
Retatrutide
new
|
2381089-83-2
|
White Powder
|
API QC
|
GLP-1, GIP, GCG single target, dual target, three target receptor agonists, weight loss
|
Cagrilintide
new
|
1415456-99-3
|
White Powder
|
API QC
|
Cagrisema (Somaluti Peptide+Kagrilin Peptide) combination to lose weight, phase 3 clinical clinical
|
Linaclotide
new
|
851199-59-2
|
White Powder
|
API QC
|
Everbone syndrome is easy to syndrome, constipation
|
90779-69-4
|
White Powder
|
API QC
|
Specific reduction of visceral fat
|
|
14636-12-5
|
White Powder
|
API QC
|
Specific reduction of visceral fat
|
|
69440-99-9
|
White Powder
|
API QC
|
Immune enhancement, hepatitis B
|
Chinese diabetic people may have a total of 143 million people, accounting for 23%of the global patients with diabetes. It is the country with the most diabetic patients in the world. Among them, type II diabetes account for about 90%of the number of diabetes, and type I diabetes and gestational diabetes account for about 9 ~ 10%.
The number of global obesity in 2020 reached 1.211 billion, an increase of 58 million people from 2019, an increase of 5.04% year -on -year.In 2020, the number of obesity in China reached 220 million people, an increase of 1.10 billion from 2019, an increase of 4.77%year -on -year.
The number of patients with non -alcoholic fatty liver patients around the world is on a rise, from 1.55 billion people in 2016 to 1.76 billion in 2020, with a compound annual growth rate of 3.1%;
According to the terminal and pharmacy terminal data of Yao Rongyun Hospital, the scale of cardiovascular chemical drugs in China was close to 90 billion yuan in 2021, and the hospital terminals accounted for 74%.
Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of broken bones (fractures).
Constipation is a problem with passing stool. Constipation generally means passing fewer than three stools a week or having a difficult time passing stool. Constipation is fairly common. A lack of dietary fiber, fluids and exercise can cause constipation.